Meetings

Tuesday, October 27, 2020

Machine learning and artificial intelligence have emerged as innovative ways to maximize the data that can be generated by liver biopsy samples. The goal of this session was to review the state of the field, and dive into the logistical, technical, and regulatory hurdles that must be addressed for these technologies to go from being used in exploratory fashion to being accepted for use in clinical trials.

Tuesday, September 1, 2020

The level of discordance between pathologists, and the differences in operationalizing liver biopsy collection in trial protocols have been frequently raised as major issues and areas of concern for NASH clinical trials.

The goal of this session was to discuss issues including: inter/intra-observer variability, scoring systems, and technical and logistical considerations.